India’s life sciences industry is steadily transforming from a cost-efficient manufacturing base into a globally recognised innovation ecosystem. Backed by progressive policy reforms, an expanding biotechnology sector, robust pharmaceutical capabilities and a rapidly growing research ecosystem, the country is increasingly being viewed as a strategic partner in addressing global healthcare and biotechnology needs.
Over the last few years, India has witnessed significant momentum across biotechnology, pharmaceuticals, medical devices, contract research, genomics and advanced therapeutics. Government initiatives, increasing private investments and stronger academia-industry collaborations are creating an environment where innovation can scale alongside manufacturing excellence. As global supply chains continue to diversify, India’s integrated capabilities are strengthening its position as one of the world’s most promising life sciences destinations.
This evolution is also driving demand for specialised infrastructure. Unlike conventional industrial developments, life sciences require purpose-built ecosystems that bring together research, manufacturing, testing, regulatory support, logistics and sustainability within a single integrated environment. Dedicated life sciences parks are therefore emerging as critical enablers of the next phase of India’s biotechnology growth.
The growing confidence in India’s capabilities was visible at the recently concluded BIO International Convention 2026 in San Diego, USA, one of the world’s largest gatherings of biotechnology companies, innovators, investors, policymakers and research institutions. The convention served as a global platform for discussions around biotechnology innovation, healthcare transformation, investment opportunities and international partnerships.
Leading the Indian delegation, K. J. Srinivasa, Consul General of India in San Francisco, inaugurated the India Pavilion, highlighting India’s expanding role in the global biotechnology ecosystem. Addressing stakeholders at the convention, he emphasised that India’s scientific talent, innovation-driven policies and collaborative ecosystem are creating new opportunities for global partnerships across research, manufacturing and healthcare innovation.
The participation of Indian organisations across the life sciences value chain further reflected the country’s growing confidence on the global stage. Leading biotechnology, pharmaceutical and healthcare companies such as Dr. Reddy’s Laboratories Limited, Biocon Limited, Indian Immunologicals Limited, RxPropellant, and Kodo Lifescience were among the Indian participants engaging with global stakeholders, showcasing the country’s growing capabilities in innovation, research and advanced therapeutics. The convention also witnessed the participation of PIP Lifescience Park, an upcoming integrated life sciences industrial ecosystem being developed by Arete Group, which highlighted India’s evolving infrastructure capabilities designed specifically for biotechnology, pharmaceutical and allied life sciences industries. The collective presence of these organisations underscored India’s emergence as a globally connected life sciences ecosystem, spanning innovation, manufacturing, research, commercialisation and specialised infrastructure.
Industry experts believe that India’s competitive advantage now extends beyond manufacturing costs. The country offers one of the world’s largest pools of scientific talent, a rapidly expanding startup ecosystem, globally accredited pharmaceutical production, digital health capabilities and increasing investments in biotechnology research. When complemented with specialised infrastructure and stronger global collaborations, these strengths have the potential to establish India as a preferred destination for innovation-led life sciences investments.
Commenting on this evolving landscape, Virender Kumar, Vice President, PIP (Arete Group), said, “India’s life sciences sector is entering a defining phase where infrastructure will become as important as innovation itself. Global investors and biotechnology companies today seek integrated ecosystems that enable research, manufacturing, collaboration and scalability. Events such as BIO International Convention reaffirm that India is no longer participating merely as a manufacturing destination, but as a strategic innovation partner. The emergence of dedicated life sciences parks reflects this transition and will play a meaningful role in supporting the country’s long-term biotechnology ambitions.”
Adding to this perspective, Dimple Shah, CEO, Kodo Lifescience, said, “The global momentum around cell and gene therapy is redefining the future of medicine, shifting focus towards highly personalised and precision-driven treatments. India is well-positioned to play a significant role in this transformation, given its strong scientific talent, growing research capabilities and increasing participation in advanced therapeutics. Platforms like BIO International Convention enable meaningful collaborations and knowledge exchange, which are critical to accelerating innovation and making next-generation therapies more accessible and scalable.”
As India progresses towards becoming a global life sciences hub, success will increasingly depend on building globally benchmarked ecosystems that seamlessly connect research, industry, infrastructure and policy. International platforms such as BIO International Convention not only reinforce India’s growing credibility but also create new avenues for partnerships, technology exchange and investment. The participation of Indian companies and infrastructure developers at such forums signals that the country’s life sciences ecosystem is becoming more organised, globally connected and future-ready, strengthening India’s position in the next chapter of global biotechnology growth.